VTX002
Ulcerative Colitis
Key Facts
About Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biotech focused on developing oral small molecule therapies for diseases with high unmet medical need, primarily through inhibition of the NLRP3 inflammasome, a master regulator of inflammation. The company achieved a significant validation milestone in early 2026 with the announcement of its acquisition by pharmaceutical giant Eli Lilly, highlighting the strategic value of its platform and pipeline. Ventyx's strategy centers on targeting broad inflammatory conditions with convenient oral agents, aiming to improve upon the efficacy and tolerability of current standard-of-care treatments, including injectable biologics.
View full company profileAbout Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biotech focused on developing oral small molecule therapies for diseases with high unmet medical need, primarily through inhibition of the NLRP3 inflammasome, a master regulator of inflammation. The company achieved a significant validation milestone in early 2026 with the announcement of its acquisition by pharmaceutical giant Eli Lilly, highlighting the strategic value of its platform and pipeline. Ventyx's strategy centers on targeting broad inflammatory conditions with convenient oral agents, aiming to improve upon the efficacy and tolerability of current standard-of-care treatments, including injectable biologics.
View full company profileAbout Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biotech focused on developing oral small molecule therapies for diseases with high unmet medical need, primarily through inhibition of the NLRP3 inflammasome, a master regulator of inflammation. The company achieved a significant validation milestone in early 2026 with the announcement of its acquisition by pharmaceutical giant Eli Lilly, highlighting the strategic value of its platform and pipeline. Ventyx's strategy centers on targeting broad inflammatory conditions with convenient oral agents, aiming to improve upon the efficacy and tolerability of current standard-of-care treatments, including injectable biologics.
View full company profileTherapeutic Areas
Other Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| PALI-2108 | Palisade Bio | Phase 2 |
| ALTB-268 | AltruBio | Phase IIa |
| AIM-HI-UC | PathAI | Clinical Trials |
| Patient Stratification in Ulcerative Colitis | Enable Medicine | Research |
| Mesalazine (Lifecycle Management) | Dr. Falk Pharma | Approved/Phase 3 |
| AhR Agonist Program | Azora Therapeutics | Phase 1b |
| R-3750 | Virtici | Phase 1 |
| GPR35 Inhibitor | ThirtyFiveBio | Preclinical |
| BEN-8744 | BenevolentAI | Phase 1b |
| BT-600 | Biora Therapeutics | Phase 1 |
| Asacol® (mesalazine) | Tillotts Pharma | Approved |
| MB310 | Microbiotica | Phase 1b |